Merck & Co. (MRK) Appoints New Deputy Chief As CEO Kley's Succession Is Pondered

Merck & Co. (MRK) Appoints New Deputy Chief As CEO Kley's Succession Is Pondered

German drug and chemicals maker Merck KGaA (MRK) is once again rearranging its C-level suite, announcing Thursday that it had appointed the head of its pharma business, Stefan Oschmann, as deputy chief executive.

The move sparked speculation that Oschmann is being groomed to succeed current CEO Karl-Ludwig Kley when he does decide to move on.
  Related Jobs 
  Research Associate - Regeneron Pharma
  Scientist / Assoc. Manager - Regeneron Pharma
  Research Associate - Regeneron Pharma
  Postdoctoral Fellow - Pfizer
  Research Associate - Bristol-Myers Squibb
  Research Scientist - Gilead Sciences
  View More Jobs

Merck said that starting Jan. 1, 2015, Oschmann, 57, will share strategic management functions and representation of the company with Kley.

Merck's biopharma chief executive officer Belen Garijo, 54, will now take over Oschmann's duties as head of the Darmstadt-based company's entire pharma unit. She currently captains Merck Serono, but will now add biosimilars, consumer health and allergy treatments to her brief. - See more at: http://www.biospace.com/News/merck-co-appoints-new-deputy-chief-as-ceo-kleys/346923#sthash.vNBrpjhY.dpuf

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds